Home > Oncology > ASCO 2020 > Multiple Myeloma > Carfilzomib: no PFS benefit for multiple myeloma

Carfilzomib: no PFS benefit for multiple myeloma

Presented By
Prof. Shaji K. Kumar, Mayo Clinica, MN, USA
ASCO 2020
Phase 3, ENDURANCE (E1A11)
Featured video: Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. https://vimeo.com/440628063 In patients with newly diagnosed multiple myeloma, carfilzomib with lenalidomide and dexamethasone (KRd) did not improve progression-free survival (PFS), when compared with the current standard of care of bortezomib with lenalidomide and dexamethasone (VRd), according to results of the ENDURANCE (E1A11) trial presented by Prof. Shaji Kumar [1]. Phase 2 studies of carfilzomib have suggested good efficacy and excellent tolerability; the rationale of the phase 3 ENDURANCE trial was to determine if carfilzomib could replace bortezomib as the standa...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on